|
Docosanoyl Ethanolamide Exclusive
Cayman Chemical Item Number 10005823Description
The endocannabinoids present a rich system of central cannabinoid (CB1), peripheral cannabinoid (CB2), and non-CB receptor-mediated pharmacology that has stimulated research in many fields including memory, weight loss and appetite, neurodegeneration, tumor surveillance, analgesia, and inflammation.1↗,2↗ Docosanoyl ethanolamide is a saturated N-acylethanolamide. Non-CB receptor-mediated pharmacology of the saturated ethanolamides is still being elucidated.3↗ Other studies indicate they may have a role in the functioning of ion channels.4↗
1 Pertwee, R.G. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6 635-664 (1999).
2 Martin, B.R., Mechoulam, R., and Razdan, R.K. Discovery and characterization of endogenous cannabinoids. Life Sci 65 573-595 (1999).
3 Smart, D., Jonsson, K., Vandevoorde, S., et al. “Entourage” effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism.. Br J Pharmacol 136 452-458 (2002).
4 Oz, M., Alptekin, A., Tchugunova, Y., et al. Effects of saturated long-chain N-acylethanolamines on voltage-dependent Ca2+ fluxes in rabbit T-tubule membranes. Arch Biochem Biophys 434 344-351 (2005).
Formal Name N-(2-hydroxyethyl)-docosanamide
CAS Number 94109-05-4
Molecular Formula C24H49NO2
Formula Weight 383.7
Formulation A crystalline solid
Purity ≥98%
Stability 2 years
Storage -20°C
Shipping Room temperature in continental US; may vary elsewhere
SMILES CCCCCCCCCCCCCCCCCCCCCC(=O)NCCO
InCHI Code 1S/C24H49NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-24(27)25-22-23-26/h26H,2-23H2,1H3,(H,25,27)
InCHI Key XHFWUECSNJWBJU-UHFFFAOYSA-N |